Human medicines European public assessment report (EPAR): Vaxneuvance, pneumococcal polysaccharide conjugate vaccine (adsorbed), Pneumococcal Infections, Date of authorisation: 13/12/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Carcinoma, Hepatocellular, Date of authorisation: 20/02/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors, Date of authorisation: 26/09/2017, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Hypertension, Pulmonary, Date of authorisation: 01/10/2008, Revision: 17, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin,perindopril, decision type: , therapeutic area: , PIP number: P/0376/2022

Orphan designation: Belzupacap sarotalocan, Treatment of uveal melanoma, 13/04/2022,

Orphan designation: (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, Treatment of sickle cell disease, 19/10/2020, Positive

Human medicines European public assessment report (EPAR): Procysbi, mercaptamine, Cystinosis, Date of authorisation: 05/09/2013, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms, Date of authorisation: 11/02/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Fortacin, lidocaine,prilocaine, Sexual Dysfunction, Physiological, Date of authorisation: 15/11/2013, Revision: 12, Status: Authorised